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Abstract. Fluorescent labels are well suited as tracers for cancer drug monitoring. Identifying cellular target
regions of these drugs with a high resolution is important to assess the working principle of a drug. We inves-
tigate the applications of label-free nonresonant four-wave mixing (NR-FWM) microscopy in biological imaging in
combination with fluorescence imaging of fluorescently labeled cancer drugs. Results from human A431 tumor
cells with stained nuclei and incubated with IRdye 800CW labeled cancer drug cetuximab targeting epidermal
growth factor receptor at the cell membrane show that NR-FWM is well suited for cellular imaging. A comparison
of vibrationally nonresonant FWM imaging with vibrational resonant coherent anti-Stokes Raman scattering sig-
nals revealed nearly identical qualitative information in cellular imaging. NR-FWM is also suitable for tumor tissue
imaging in combination with fluorescence imaging of IRdye 800CW labeled, human epidermal growth factor 2
targeting cancer drug pertuzumab and provides additional information over transmission microscopy. © 2015
Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JBO.20.8.086006]
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1 Introduction
An important step in the development and testing of new tar-
geted cancer drug candidates is the acquisition of information
about their pharmacological and pharmacodynamic action.
Targeted cancer drugs are designed to bind to specific biomo-
lecules, involved in carcinogenesis and tumor growth, such as
membrane proteins or ligands, for their effectiveness. To assess
their effectiveness, the identification of target regions within a
tumor with a high, subcellular resolution is a key aspect.
Monoclonal antibodies (mAbs), such as cetuximab and tras-
tuzumab, are currently used as targeted cancer drugs.1
Cetuximab and trastuzumab are targeted to, respectively, the
extracellular domain of human epidermal growth factor receptor
(EGFR) and the human epidermal growth factor 2 (HER2)
receptor at the cell membrane. Both EGFR and HER2 are impli-
cated in regulating cell growth and proliferation and are fre-
quently overexpressed, mutated, or dysregulated in certain
cancer types. mAbs with their high affinity are suitable candi-
dates for treatment, or when radioactively or fluorescently
labeled, as tracer for tumors expressing these targets.2–4
One of the strategies to use an mAb as an imaging tracer for
tumors is the labeling of the antibody with a fluorescent dye.
Studies involving the above-mentioned mAbs use IRdye
800CW for antibody labeling.4 The use of a dye with absorption
and emission spectra in the 800 nm wavelength region circum-
vents the influence of autofluorescent molecules, such as
reduced nicotinamide adenine dinucleotide and flavin adenine
dinucleotide and other native proteins, since these emit no
red-shifted autofluorescence in this wavelength region.5 Also,
because IRdye 800CWabsorbs and emits in the optical window
of tissue, the loss of excitation light and fluorescence emission
due to absorption and scattering by tissue is minimal.6 IRDye
800CW has been tested for toxicity and approved by the
FDA for human use.7 This combination of properties makes
this particular dye optimal for fluorescence imaging in vivo.8
Detection of drugs has been investigated extensively both
in vivo and in model systems to assess the distribution of the
drug in both healthy organs and malignant tumor tissue and
to localize the binding targets of the cancer drugs. Currently,
the microscopic localization and distribution of cancer drugs
is most commonly investigated using immunohistochemistry
in combination with hematoxylin and eosin staining.4,9,10
Simultaneously, information about the location of the different
cellular components is obtained mostly using fluorescent
probes targeted to specific cellular components.11 Immuno-
histochemistry has a limited resolution, and the addition of
stains to visualize, for example, nuclei or blood vessels enables
only selective imaging of the targets of the stains but does not
provide information about other structures. The effects of add-
ing stains to a biological system are not always known and could
influence the biological process under investigation. Although
the location of other cell components can be determined with
a high three-dimensional (3-D) resolution using multiphoton
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excitation of stains,12 this technique is still limited in the sense
that it is only sensitive to cellular structures that can be stained.
Conventional (linear) microscopy techniques, such as bright-
field and phase contrast microscopy, are able to provide mor-
phological information about the sample, but only with a low
resolution in 3-D. In contrast, nonlinear optical imaging tech-
niques, such as coherent anti-Stokes Raman scattering
(CARS), provide a label-free, inherently confocal method to
image cellular morphology with a high resolution.
CARS microscopy is a nonlinear optical technique that is
widely applied in biological imaging of cells and tissue,13 im-
aging of pharmaceutical compounds,14 and imaging of drug dis-
tribution in cells and tissue.15,16 While most microscopy
techniques require the addition of contrast agents, such as fluo-
rophores, CARS microscopy techniques are label-free since
they exploit differences in vibrational energy levels between dif-
ferent chemicals. When the energy difference between the two
input beams, pump (ωp) and Stokes (ωs), is equal to the energy
of a molecular vibration, an additional amplitude in the anti-
Stokes field is generated at frequency ωas ¼ 2ωp − ωs. Due
to the quadratic dependence of the CARS signal on the incident
pump laser power, the anti-Stokes field is generated mostly in
focus. CARS microscopy, thus, enables mapping of molecular
information with a high resolution in x, y, and z. A common
contribution to the total anti-Stokes signal in CARS imaging,
however, is the presence of a nonresonant four-wave mixing
(NR-FWM) signal, also referred to as the nonresonant back-
ground.17 This contribution is dependent on the electronic polar-
izability only. We will show that the vibrationally nonresonant
FWM process is useful for morphological imaging and can be
combined with molecule-specific linear fluorescence imaging
of IRdye 800CW labeled mAbs cetuximab and pertuzumab.
Cetuximab and pertuzumab are used to target EGFR and HER2,
respectively. We also combine NR-FWM microscopy with two-
photon excitation fluorescence (TPEF) imaging of Hoechst
33342 or 4’,6-diamidino-2-phenylindole (DAPI) stained nuclei,
respectively. For this, both cell and xenograft tumor tissue
samples are used. Figure 1 shows an energy level diagram
of the mentioned optical processes. Morphological NR-FWM
imaging here is based on spatial variations in the molecular and
electronic density in the sample and, therefore, spatial varia-
tions of the amplitude of the generated anti-Stokes signal.
The generated NR-FWM intensity is compared with vibra-
tional resonant CARS signals in order to extract insights on
the advantages and drawbacks of the CARS and NR-FWM im-
aging modalities.
2 Theoretical Background
This section describes the theoretical background of CARS,
NR-FWM, and the relation between the total anti-Stokes signal
and the third-order nonlinear susceptibility χ3.
The total anti-Stokes signal (IAS) is related to the third-order
susceptibility (χ3). The susceptibility χ3 is generally described
by a vibrationally resonant (χ3R) and a vibrationally nonresonant
or electronic part (χ3NR).
17
EQ-TARGET;temp:intralink-;e001;326;480IAS ∝ jχ3R þ χ3NRj2 ¼ jχ3Rj2 þ 2χ3NRRe½χ3R þ jχ3NRj2: (1)
Here the resonant part describes the interaction of the pump
and Stokes field with a molecule through a coupling with two
vibrational energy levels in the electronic ground state of a
molecule, whereas the nonresonant contribution describes
interactions of the pump and Stokes field with a molecule
through a (often nonresonant) coupling to excited electronic
Fig. 1 (a) Energy level diagram of linear fluorescence, (b) two-photon excited fluorescence, (c) electronic
resonant (NR) four-wave mixing (FWM), (d) electronic nonresonant FWM, and (e) vibrational resonant
FWM [or coherent anti-Stokes Raman scattering (CARS)]. The frequency used for one- and two-photon
excitation is ωex (in red), with corresponding emission frequency ωem [dark red and blue in the linear and
two-photon excitation fluorescence (TPEF) energy level diagram, respectively]. ωp (in purple) and ωs
(in orange) are the applied pump and Stokes fields in nonresonant FWM or a CARS experiment,
and ωas (in green) indicates the generated anti-Stokes field.
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states to generate an anti-Stokes photon. In the latter process, no
vibrational energy level is probed. An anti-Stokes signal is also
generated when the difference frequency between the pump and
probe beams is far from any vibrational resonance in the elec-
tronic ground state. This off-resonance contribution also con-
tributes nonresonant signal to IAS [Eq. (1)]. The spectrum of
the interferometric mixing term 2χ3NRRe½χ3R in Eq. (1) rapidly
changes when ωp − ωs ≈ ωvib, i.e., in the neighborhood of a
vibrational resonance. This spectral response arises from the
rapidly changing vibrational phase that is associated with the
vibrational resonant transition, with respect to the phase of
χ3NR. Although the processes described by χ
3
NR are usually
assumed to have a flat phase, resulting in a purely real χ3NR, elec-
tronically resonant FWM may also contribute a phase change to
the anti-Stokes signal. Far away from excited state electronic
resonances, this phase change is mostly small and contributes
a constant phase, a flat phase, to the total phase in a CARS
spectrum.
The total generated anti-Stokes intensity depends not only on
the material property χ3 but also on the cubic product of inten-
sities of the pump and Stokes beams.18
EQ-TARGET;temp:intralink-;e002;63;503IAS ∝ I2pumpIStokes: (2)
The aim of CARS experiments is commonly to acquire
material-specific information by probing vibrational resonances.
The signal-to-noise ratio (SNR) of this signal is reduced due to
the nonresonant contributions to IAS. Therefore, reduction of
the NR-FWM signals while generating vibrational resonant sig-
nals is a major goal in CARS research. Methods implemented
in CARS microscopy to reduce the nonresonant background
are based on well-known techniques in CARS spectroscopy
and include polarization CARS,19,20 frequency modulated
CARS,21 or heterodyne CARS.17 These techniques improve
the SNR of the CARS signal. Although the removal of the
NR-FWM signals increases the chemical specificity of resonant
CARS techniques, the vibrationally nonresonant FWM signals
could be used to generate contrast in samples. Because the vibra-
tionally nonresonant FWM signal contributions are generated by
all sample components, unlike the resonant contributions, these
nonresonant contributions can be used to image cellular and tis-
sue structures.
Some work on NR-FWM imaging of biological samples has
been performed. Mahou et al.22 applied NR-FWM microscopy
to image C. Elegans worms and zebra fish embryos and showed
that spatial variations in χ3NR can be used to image cells and cell
substructures. Comparisons among NR-FWMmicroscopy, third
harmonic generation (THG), second harmonic generation
(SHG), and TPEF by Mahou et al.22 showed that each of
these techniques has a specific advantage: NR-FWM micros-
copy provides label-free contrast in the sample based on spatial
variations in χ3. THG enables label-free imaging of interfaces in
the sample due to large differences in χ3 at interfaces, but
requires higher power than NR-FWM for a 250 fs pulse dura-
tion. SHG and TPEF can be used for (label-free) molecule-spe-
cific imaging.
Min et al.23 applied NR-FWM microscopy with a small dif-
ference in wavelength between pump and Stokes beams (near-
degenerate NR-FWM) to image live A549 human nonsmall cell
lung cancer cells and muscle and brain tissue morphology. Min
et al.23 used near-degenerate electronic resonant FWM micros-
copy to image absorbing but nonfluorescent molecules by tun-
ing the pump wavelength to match the absorption band of the
molecule. Potma et al.17 showed that the nonresonant FWM
intensity produced at different locations in a single NIH-3T3
mouse fibroblast cell can be used to generate contrast in the
cell. The recorded NR-FWM image of a single NIH-3T3 cell
shows the cell membrane and the nucleus and the overall
morphology.
3 Materials and Methods
3.1 Sample Preparation
Cetuximab (Erbitux®, Merck KgaA) and pertuzumab (Perjeta®,
Roche) are buffer exchanged into 0.9% NaCl using Vivaspin 2
ultracentrifuge concentrators (GE Healthcare). After pH is set to
9.0 with 0.2 M sodium carbonate, IRDye 800CW-NHS ester in
dimethyl sulfoxide (DMSO) at 5 mg∕mL (Licor Biosciences) is
added in a 1∶3 (cetuximab) and 1∶2 (pertuzumab) molar ratio of
antibody to IRDye 800CW-NHS and incubated during 1 h at 20°
C. Purification of antibody-dye conjugates from unreacted dye
is performed using PD10 desalting columns (GE Healthcare).
Final concentration, purity, and labeling efficacy are analyzed
using size-exclusion, high-performance liquid chromatography
with absorbance detection wavelengths at 220, 280, and 780 nm.
Cetuximab-IRDye 800CW yielded 2.6 dye-molecules∕mAb,
whereas pertuzumab-IRDye 800CW yielded 1.7dye-molecules∕
mAb; both products were over 95% pure. Cetuximab-IRdye
800CW is used for single cell imaging, and pertuzumab-IRdye
800CW is used for the breast cancer model (vide infra). Because
the mass ratio between a single antibody and a single IRdye
800CW molecule is between 150 kDa to 1 kDa and 170 kDa
to 1 kDa, the obtained labeling ratio for cetuximab and pertu-
zumab antibodies has only a small effect on the total weight of
the original antibody. Also, as the antigen binding site of the
antibodies is very small compared to the total antibody, it is
unlikely that the antigen binding site is occupied by one or
more IRdye 800CW molecules at the mentioned labeling ratios.
Cellular imaging is performed using the EGFR-overexpress-
ing human squamous cell carcinoma cell line A431. A431 cells
are cultured in Dulbecco’s modified Eagles medium with high
glucose supplemented with 10% fetal bovine serum.
Cetuximab-IRdye 800CW is added to the cells at a concentra-
tion of 20 μg∕mL, which amounts to 10 μg for a 2 cm2 mono-
layer of cells. This results in 4.1 × 1013 antibody molecules per
120,000 cells. The incubation time is 30 min at 37°C. The cells
are fixed in a 4% paraformaldehyde solution in phosphate-
buffered saline (PBS) for 15 min. Nuclei are stained by a
0.1 μg∕mL Hoechst H33342 solution during 20 min incubation.
All animal experiments are approved by the Institutional
Animal Care and Use Committee of the University of
Groningen. For tissue imaging, male Balb/C nude mice (BALB/
cOlaHsd-Foxn1nu, Harlan) are used. Xenografts are inoculated
subcutaneously using HER2 overexpressing SK-BR-3 breast
cancer in a 1∶1mixture of PBS and matrigel. When tumors mea-
sured 100 to 200 mm3, mice are injected with 100 μg pertuzu-
mab-IRdye 800CW via the penile vein and sacrificed six days
postinjection. Xenografts are excised and fixed in 4% neutral
buffered formaldehyde solution, paraffin embedded, and slices
with a thickness of 4 μm are cut. Slices are placed on a cover
glass using a warm water bath and dried overnight at 60°C.
Subsequently, slices are de-paraffinized and the nuclei stained
with DAPI.
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3.2 Optical Microscopy
Linear fluorescence, nonlinear fluorescence, and CARS micros-
copy are performed on an Olympus IX71 inverted microscope,
equipped with a FluoView300 scan unit. A set of galvo mirrors
scans the beams over the sample to generate a two-dimensional
image.
The excitation light is produced by an optical parametric
oscillator (OPO, APE Berlin GmbH, Germany) pumped by a
22 ps pulsed, frequency-doubled Nd∶YVO4 1064 nm wave-
length laser (Coherent Paladin). The narrowband signal output
of the OPO is tunable from 710 to 980 nm by changing the crys-
tal temperature and a Lyot filter installed in the OPO cavity.24
The idler output of the OPO is not used.
A part of the laser fundamental at 1064 nm beam is directed
to the microscope. Before it enters the microscope, it is spatially
overlapped with the OPO signal beam using a dichroic mirror
and temporally overlapped using a delay stage in the 1064 nm
beam path. The signal beam and fundamental beam are used as
pump and Stokes beam, respectively, for the generation of
CARS and NR-FWM signals. For vibrationally resonant
CARS images, the frequency difference between the signal
and 1064 nm beam is set to match the CH2-stretch vibrations
at 2845 cm−1. For NR-FWM imaging, the frequency difference
is set to 2698 cm−1, within the silent region for Raman spectros-
copy.25 At this frequency, the anti-Stokes signal contains no
vibrational resonant contributions from biomolecules. The
wavelength of the anti-Stokes signal was 676 nm for a difference
of 2698 cm−1 between the pump and Stokes beam. The fre-
quency of 2698 cm−1 was selected to optimize for the wave-
length-dependent transmission efficiency of the setup in
combination with the available optical filters as well as the
wavelength-dependent detection efficiency of the photodetector.
For SHG, only the 1064 nm beam is used.
For clarification, an overview of the different modalities with
corresponding excitation wavelengths is shown in Fig. 2.
Figure 2 also shows a measured averaged background-free
spontaneous Stokes Raman spectrum of an A431 cell. The spon-
taneous Raman spectrum was measured on a different micro-
scope described elsewhere,26 using a 647.1 nm continuous
wave laser and a home-built spectrometer. This spectrum was
measured at the Stokes side, but plotted at the anti-Stokes
side of the pump beam (indicated by the magenta arrow labeled
ωp) used in the CARS modality at 2845 cm−1. In this figure, the
spectral locations of the imaging modalities NR-FWM, CARS,
TPEF, and linear fluorescence explained in Fig. 1 are shown
using corresponding color-coding. The IRdye 800CWexcitation
beam is shown in red at 770 nm (ωex), with corresponding emis-
sion at 800 nm in dark red (ωem). The two-photon excitation
modality used to excite Hoechst 33342 and DAPI is indicated
by the two red arrows at 385 nm wavelength, representing the
two 770 nm photons involved. The corresponding Hoechst
33342 emission is represented by the blue arrow at 400 nm
(ωem). From the spontaneous Raman spectrum, it can be seen
that CARS at 2845 cm−1 (green solid, ωas) is measured at res-
onance in the CH-stretch region and that the NR-FWM at
2698 cm−1 (green dashed, ωas) is measured off-resonance.
Note that the 2845 cm−1 peak is relatively small compared to
the total intensity in the CH-stretch region. This could be differ-
ent in CARS experiments, since the signals in CARS experi-
ments are generated coherently. The NR-FWM anti-Stokes
signal at 2698 cm−1 is represented by a dashed line. In our
experiments, the wavelength of the pump beam is tuned,
such that only the wavenumber axis represents the NR-FWM
modality correctly. The Stokes beam, at 1064 nm, is shown
at the Stokes side of the pump beam in orange (ωs). For exci-
tation of the IRdye 800CW fluorophore, the signal beam is
tuned to 770 nm. A power of 40 μW was used. For TPEF of
Hoechst 33342 and DAPI, the power of the signal beam at
770 nm was increased to 50 mW. Resonant CARS and
FWM images were recorded at excitation powers of 50 and
95 mW for the signal beam and 1064 nm for Stokes beam,
respectively.
Both beams are focused on the sample using a 60 × 1.2 NA
Olympus water immersion objective (UPLANSAPO IR,
Olympus). IRdye 800CW, Hoechst 33342, and DAPI fluores-
cence are collected using the 1.2 NA objective and detected
with a photomultiplier tube (PMT, Hamamatsu, R3896) in back-
ward detection mode. Vibrationally resonant CARS and the NR-
FWM signals are detected in the forward direction using a 0.55
NA condenser. Appropriate filters were placed in front of the
PMT (Hamamatsu, R3896) to reject the pump and Stokes
beams. Images are recorded with a pixel dwell time of 10 micro-
seconds and typically three averages. Nyquist sampling criteria
are satisfied for the one-photon and multiphoton imaging
modalities. Transmission images were recorded by detecting
the transmitted intensity of the pump beam at 770 nm while
the beam scans over the cell, using a fiber coupled to a
PMT. All images were corrected for the spatial variations in col-
lection efficiency of the generated signals. This was done by
measuring the CARS signal of a droplet of DMSO, which is
expected to generate a homogeneous CARS intensity in the
field of view. Any nonhomogeneous intensities in the image
Fig. 2 Spontaneous Stokes Raman spectrum plotted at the anti-
Stokes side of the pump beam at 0 cm−1. The Raman spectrum is
divided in the CH-stretch region (−3200 to −2500 cm−1) and the
fingerprint region (−1800 to 0 cm−1). The imaging modalities are
also indicated in this figure at the corresponding wavelength with
respect to the Raman spectrum. The location of the different excitation
beams and the detected signals as shown in Fig. 1 are overlaid on the
Raman spectrum. The detected signals are the vibrationally nonreso-
nant FWM signal at 2698 cm−1 (dashed green, ωas), vibrationally res-
onant CARS (solid green, ωas), Hoechst TPEF emission (blue, ωem),
and IRdye 800CW fluorescence emission (dark red, ωem).
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correspond to spatial variations in collection efficiencies. This
signal has been used for correction of the images.
4 Results and Discussion
4.1 Cellular Imaging
In Fig. 3(c), a laser light transmission image of a single, DAPI-
stained, A431 cell incubated with cetuximab-IRdye 800CW is
shown. Figure 3(a) shows the corresponding fluorescence emis-
sion image of cetuximab-IRdye 800CW. Figure 3(b) shows a
TPEF image of Hoechst 33342, indicating the location of the
cell nucleus with an inherently confocal resolution. The
image size is 78 × 78 μm consisting of 1024 × 1024 pixels.
All images are recorded at the same z-position of the objective
and the same field of view.
The transmission and Hoechst 33342 images provide infor-
mation about cellular morphology, whereas the fluorescence
image provides information about the location of the cancer
drug cetuximab with high selectivity. The combination of
images suggests that the fluorescently labeled cetuximab is
present mainly at the cell membrane, as expected; the shape
of the fluorescence emission completely surrounds the nucleus
in the two-dimensional image plane. Some fluorescence inten-
sity can be seen from the distal ends of the cell or from intra-
cellular regions. By comparing the fluorescence emission image
[Fig. 3(a)] with the transmission image [Fig. 3(c)], the fluores-
cence emission appears to colocalize with the cell membrane.
Because the signals recorded in the transmission and linear
fluorescence image also contain contributions from out-of-
focus regions in the cell, it is difficult to determine the exact
location of the fluorescence emission image with respect to
the cell membrane and other cellular components. Both dis-
cussed methods, Hoechst staining and transmission microscopy,
have their limitations in the sense that only information about
the location of a certain cellular compound (nucleus stained with
Hoechst 33342) is obtained or that the depth resolution is rel-
atively low (transmission image).
In Fig. 3, the one- and two-photon fluorescence modalities
are combined with the nonlinear label-free optical imaging
modalities CARS and NR-FWM microscopy in Figs. 3(d)
and 3(e), respectively. Figure 3(d) shows a CARS image at
2845 cm−1, probing the CH2 stretching vibrations, predomi-
nantly present in lipids.27 This image shows the vibrationally
resonant anti-Stokes signals arising from lipid structures in
the A431 cells on top of the vibrationally nonresonant FWM
signals that are also present at this vibrational frequency. An
image of the same cell far from vibrational resonances was
recorded at 2698 cm−1 [Fig. 3(e)], to qualitatively compare the
differences and similarities between the image at resonance
2845 cm−1 [Fig. 3(d)] and an off-resonance image. It can be
observed from a comparison between Figs. 3(d) and 3(e) that
the vibrationally nonresonant FWM contribution dominates
the response in the image recorded at resonance. A large part
of the signal could also arise from the interferometric mixing
term as stated in Eq. (1). The interferometric mixing term domi-
nates over the purely vibrational resonant term when the
Fig. 3 Multimodal images of fixed A431 cells, incubated with cetuximab-IRdye 800CW and stained with
Hoechst 33342. The images show (a) the IRdye 800CW fluorescence emission image, (b) Hoechst
33342 TPEF image, (c) laser transmission image, (d) CARS image at 2845 cm−1, and (e) NR-FWM
image at 2698 cm−1. The size of the scale bar shown in (c) is 5 μm [relevant for panels (a) to (e)].
The intensity profile plot of the white line in (a), (d), and (e) is shown in (f). The black line shows the
average background intensity. The arrows in (d) indicate the lipid droplets (LDs) that were used for quan-
titative analysis in Table 1.
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nonresonant contributions are large compared to the vibrational
resonant contributions.
The image in Fig. 3(d) shows the morphology of the cell. The
cell membrane, cell nucleus, and two nucleoli can be identified.
The nucleoli are specialized areas in the nucleus, which correlate
with the dark spots in the Hoechst TPEF emission image in
Fig. 3(b), as indicated by the purple arrows. Lipid droplets pro-
duce a large anti-Stokes intensity at 2845 cm−1. A large amount
of lipid droplets is located in the upper left corner of the cell in
Fig. 3(d). Also, in other regions of the cell, lipid-rich structures
can be identified. The lipid droplets, nucleoli, and the nucleus
can also be identified in the NR-FWM image in Fig. 3(e).
Intensity profiles are shown in Fig. 3(f). The profiles show
the intensity of the IRdye 800CW fluorescence emission, the
CARS, and the NR-FWM signals as measured along the
white line in Figs. 3(a), 3(d), and 3(e). The colors of the curves
in Fig. 3(f) correspond with the lines in the figures marked with
identical colors. These profiles are shown to compare the signal
measured in the off-resonance image with the signal measured in
the image on resonance. In both the CARS and NR-FWM inten-
sity line profiles, large variations in intensity are observed as a
function of position in the cell. This can be compared with a
region outside the cell, where a homogeneous body of PBS gen-
erates a uniform anti-Stokes signal. From this, it can be con-
cluded that water inside the cell has a significant contribution
to the total anti-Stokes signal. Other molecules, such as organic
molecules inside the cell soma, could also contribute to the total
CARS signal.
In Fig. 3(f), two features, a nucleolus and a lipid droplet, are
indicated with a star at 11 and 20 μm, respectively, in the
2845 cm−1 intensity profile plot. In the 2845 cm−1 profile,
the lipid droplet signal is higher compared to the (nonresonant)
signal generated by water in the 2698 cm−1 profile plot. This
indicates the presence of additional mixing term or vibrationally
resonant contributions to the total lipid droplet signal at
2845 cm−1.
Although the NR-FWM image at 2698 cm−1 is far from any
vibrational resonance (Fig. 2), a high contrast can be observed
[Fig. 3(e)]. The contrast in the NR-FWM image arises from a
combination of molecular density differences and third-order
refractive index differences. From the small difference in
lipid droplet signal and the almost identical intensity profile
in the CARS and NR-FWM images, we can conclude that
the nonresonant background has significant contributions to
the overall anti-Stokes signals at 2845 cm−1. The vibrationally
resonant contributions to the signal increase the intensity and
contrast, but is not necessary for imaging the cellular morphol-
ogy [see Figs. 3(d) and 3(e)]. It should be noted that, in general,
the ratio between vibrationally resonant and NR-FWM signals
depends on the Raman scattering cross-sections, feature sizes,
and the electronic properties of the material. It is apparent
that an excellent contrast can be obtained with NR-FWM imag-
ing of cells, i.e., without the need to stimulate vibrationally res-
onant contributions contained in χ3R.
Figure 4(a) shows a combination of NR-FWM with TPEF
and linear fluorescence. This figure shows that the fluorescence
emission from cetuximab-IRdye 800CW (false color-coded as
red) colocalizes with the cell membrane. Out-of-focus fluores-
cence emission, however, limits the axial resolution of the fluo-
rescence image. The axial resolution of linear fluorescence is on
the order of 2 μm, which is comparable to the average cell thick-
ness. The lateral resolution of TPEF is on the order of 500 nm,
which enables a better localization of the probe volume in the
cell. The local minima in the Hoechst 33342 stained region
colocalize with the nucleoli that are also clearly distinguishable
in the NR-FWM image. Figure 4(b) shows an image obtained by
subtracting the NR-FWM image at 2698 cm−1 from the CARS
image at 2845 cm−1. In this difference figure, the cell shape and
lipid droplets can be identified. It can be seen here that the ad-
vantage of CARS imaging over NR-FWM imaging is mainly its
suitability for molecule-specific imaging in this particular
example.
Figure 5 shows a CARS [Fig. 5(a)] and NR-FWM [Fig. 5(b)]
mixing image of a single A431 cell. The cellular morphology
can be identified in both images. In the line profile plot in
Fig 5(c), it can be seen that the lipid droplets generate more sig-
nal in the CARS image, as is also shown in Fig. 4(b).
For a quantitative comparison between the CARS and NR-
FWM signals, the SNR is calculated for several regions in the
cell shown in Figs. 3 and 5. The SNR is calculated according to
Eq. (3).
Fig. 4 (a) Overlay image of cetuximab-IRdye 800CW fluorescence emission, Hoechst 33342 TPEF fluo-
rescence emission, and NR-FWM image at 2698 cm−1 (b) and difference figure NR-FWM at 2698 cm−1
subtracted from CARS image at 2845 cm−1.
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EQ-TARGET;temp:intralink-;e003;63;505SNR ¼ Mean signal value
Standard deviation background
: (3)
Table 1 shows the SNR for three lipid droplets indicated in
Fig. 3 and for two different regions of the cell cytoplasm in both
the CARS and NR-FWM images. Table 2 shows the SNR for
three lipid droplets indicated in Fig. 5 and also for two different
regions of the cell cytoplasm. In these two tables, it is shown that
the SNR of the lipid droplets is approximately twice as large in
the CARS image compared to the NR-FWM image. The SNR of
the cell cytoplasm is only slightly larger in the CARS image
compared to the NR-FWM image. Here the SNR in the
CARS image increases only by an approximate factor 1.2 com-
pared to the NR-FWM image.
The molecular properties of IRdye 800CW and the chosen
excitation field frequencies cause photobleaching of IRdye
800CWwhile recording the TPEF, CARS, or NR-FWM images.
This photodamage is a result of the relatively high excitation
power required for the latter three modalities. Consequentially,
first, the image of the linear fluorescence of IRdye 800CW was
acquired and only then the nonlinear imaging modes were car-
ried out.
4.2 Tumor Tissue Imaging
Nonlinear imaging in combination with imaging of fluores-
cence-labeled cancer drugs was also applied to tumor tissue.
Tumor tissue was imaged by collecting the single-photon
excited fluorescence from pertuzumab-IRdye 800CW, TPEF
of Hoechst, CARS at 2845 cm−1, and NR-FWM at 2698 cm−1.
The tumor tissue was derived from an inoculated human breast
cancer cell line SK-BR-3, which overexpresses HER2, xeno-
grafted in a mouse that was injected with the anti-HER2 anti-
body pertuzumab-IRdye 800CW.
Figure 6 shows the result of multimodal imaging of slices of
tissue from the tumor xenograft, recorded at the same position in
the sample. The distribution of pertuzumab-IRdye 800CW in the
SK-BR-3 tumor is visualized in Fig. 6(a). Clearly, pertuzumab-
IRdye 800CW is nonuniformly distributed in this tumor section
and in individual cells. The location of the cell nuclei is sub-
sequently visualized in the DAPI TPEF image in Fig. 6(b).
The CARS image and the NR-FWM image in Figs. 6(c) and
6(d) show the morphology of the tumor tissue based on spatial
Fig. 5 (a) CARS and (b) NR-FWM image of a single A431 cell, recorded at 2845 and 2698 cm−1, respec-
tively. The field of view is 23 × 23 μm2. (c) The line profile plots for the CARS and NR-FWM image are
shown including the black line, indicating the average background intensity. Distance line starts at 0 μm
at the left side of the image. The arrows in (a) indicate the LDs that were used for quantitative analysis
in Table 2.
Table 1 Signal-to-noise ratio calculated for several lipid droplets







Lipid droplet 1 19.89 2.45 13.25 2.30
Lipid droplet 2 28.20 5.80 16.30 2.28
Lipid droplet 3 14.74 2.73 9.40 2.20
Cell cytoplasm
region 1
10.01 1.43 8.00 1.13
Cell cytoplasm
region 2
15.73 2.07 12.65 1.62
Note: CARS, coherent anti-Stokes Raman scattering; NR-FWM, non-
resonant four-wave mixing.
Table 2 Signal-to-noise ratio calculated for several lipid droplets







Lipid droplet 1 14.72 4.14 6.48 0.61
Lipid droplet 2 12.65 3.05 6.40 1.21
Lipid droplet 3 14.30 3.87 6.58 0.83
Cell cytoplasm
region 1
5.67 1.17 4.88 0.85
Cell cytoplasm
region 2
5.73 0.91 5.11 0.72
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variations in χ3. In both these figures, cell nuclei can be iden-
tified. Also, in tissue sections, the nucleoli can be discriminated
from surrounding nuclear components. Contrast between lipid-
rich regions and tumor cells in the tumor section is clearly vis-
ible in both CARS and NR-FWM images. In the IRdye 800CW
and DAPI overlay image in Fig. 6(g), the fluorescence emission
shows the location of the cytoplasmic membrane of cells within
the tumor. The fluorescence emission colocalizes with the boun-
dary of some tumor cells that can be identified in the NR-FWM
and CARS images (indicated with the green arrows in Fig. 6).
This implies that the membrane has been stained, which is
expected, because pertuzumab binds to receptor molecules on
the cell membrane. Some nuclei can be identified in Fig. 6(g)
that are not surrounded by an IRdye 800CW stained cytoplas-
mic membrane. These nuclei are smaller and differently shaped
compared to the nuclei surrounded by an IRdye 800CW stained
membrane. These cells could be native mouse cells present in
the tumor. Also, the fact that the IRdye 800CW positive cells are
grouped together and that the cells without a membrane stain are
located outside of this region suggests that nonstained cells are
native mouse cells. However, washing steps in the de-paraffini-
zation step could also result in loss of fluorescent tracer from
parts of the tumor tissue slice. Furthermore, lack of fluorescence
could be due to necrosis in parts of the xenograft or represent
residual pockets of Matrigel used in the xenografting of
SK-BR-3 cells.
NR-FWM and CARS microscopy both provide significantly
better contrast in this tumor sample than transmission micros-
copy, as can be seen from a comparison of the laser light trans-
mission [Fig. 6(e)] with the NR-FWM and CARS images
[Figs. 6(c) and 6(d)]. Especially due to the thickness (4 μm)
of this tumor slice, NR-FWM and CARS are more suitable
techniques for morphological imaging of this sample than trans-
mission imaging. This is because the detected signal in CARS or
NR-FWM is generated in a small confocal-like spot, whereas
the transmission beam is affected by out-of-focus regions in
the sample. Comparing the CARS and NR-FWM images and
the corresponding line profile plots in Fig. 7, differences in rel-
ative intensities are observed. Both techniques provide label-free
contrast in cellular and tissue imaging, where the vibrationally
resonant part in the CARS images provides additional chemical
Fig. 6 Multimodal images of tumor slices obtained from a mouse bearing human breast cancer SK-BR-3
xenograft tumor, injected with pertuzumab-IRdye 800CW. The images show (a) distribution of pertuzu-
mab-IRdye 800CW, (b) 4’,6-diamidino-2-phenylindole (DAPI) stained cell nuclei, (c) tumor morphology
using CARS at 2845 cm−1, (d) tumor morphology using NR-FWM at 2698 cm−1, (e) transmission image
of tumor section, (f) collagen distribution using second harmonic generation (SHG), (g) overlay of per-
tuzumab and DAPI image, showing the distribution of pertuzumab with respect to the cell nuclei, and
(h) overlay of collagen SHG and NR-FWM image. The size of the scale bar in (e) is 10 μm and is relevant
for all panels from (a) to (h). The image size is 78 × 78 μm and consists of 1024 × 1024 pixels. The lines
in (c) and (d) indicate the region used for the profile plot in Fig. 7.
Fig. 7 Intensity profile plot of the blue (CARS image) and green (NR-
FWM image) line in Fig. 6. Distance line starts at 0 μm at the left side
of the image.
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specific contrast. The distribution of collagen in the tumor is
shown in Fig. 6(f), using SHG and overlaid with the NR-
FWM image [Fig. 6(h)].
The suitability of NR-FWM imaging was demonstrated both
in cells incubated with cetuximab-IRdye 800CW as well as in
tumor xenograft tissue from animals injected with pertuzumab-
IRdye800CW, respectively. Both cancer drugs show a mem-
brane staining, as expected. In tumor tissue, where other com-
ponents beside cells are also present, NR-FWM imaging is very
suitable for morphological imaging.
5 Conclusion
We have demonstrated the potential of a multimodal microscopy
combination of linear NIR fluorescence imaging with NR-FWM
imaging to investigate the distribution of tumor-targeting drugs,
such as cetuximab and pertuzumab, in cells and tissues. We have
compared CARS imaging with NR-FWM imaging and have
found that NR-FWM is an excellent approach to label-free cel-
lular and tissue morphological imaging. The contrast in NR-
FWM is based on spatial differences in χ3, which is of a similar
quality as vibrationally resonant CARS. It can be concluded that
the vibrationally resonant contribution to the total anti-Stokes
signal is not essential to provide high-contrast images based
on general total χ3.
From comparing CARS and NR-FWM quantitatively, it can
be concluded that small lipid droplets inside cells provide
approximately a twofold SNR compared to NR-FWM. The con-
trast in regions of the cell that contain mostly cytoplasm and
without clearly visible organelles shows minor differences
between CARS and NR-FWM images.
By creating a hybrid microscope system that integrates linear
fluorescence, TPEF, SHG, laser light transmission imaging and
coherent anti-Stokes Raman scattering, and NR-FWM, it is pos-
sible to selectively image fluorescently labeled cancer drugs and
obtain morphology information about target location of the
drugs in the cell or tumor tissue.
For future work, a combination of NR-FWM with confocal
linear fluorescence will provide a better resolution for fluores-
cence imaging and could be used for numerous applications in
biological imaging, including resolving the subcellular distribu-
tion of fluorescently labeled drugs in axial and lateral direction.
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